UroToday

EAU 2026: Time-Dependent Survival Benefit of Enzalutamide + Radium-223 in mCRPC: Reconstructed Analysis of the PEACE-3 Trial

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
UroToday

EAU 2026: Debate: Optimal Management of De-Novo Oligometastatic Disease: Radiotherapy – Treat All You Can See

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...
UroToday

EAU 2026: Optimizing the Timing of Docetaxel After Androgen Receptor Pathway Inhibitor Therapy: Development and Validation of a Novel Prognostic Model in mCR…

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
UroToday

EAU 2026: Safety and Skeletal Event Profile of Radium-223 Combined with Enzalutamide in mCRPC: A Multicenter Retrospective Analysis in Japan

Grade ≥3 hematologic toxicities were uncommon (anemia 6.1%, neutropenia 5.2%), and non-hematologic adverse events were rare. The absence of bone-modifying agents was the strongest predictor of ...
UroToday

EAU 2026: External Validation of a Prognostic Risk Model for Overall Survival After Radium-223 Treatment in mCRPC

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...
UroToday

EAU 2026: Impact of Girentuximab Based Radionuclide Imaging in Patients with RCC on Virtual Tumor Board Decision Making: An Interim Analysis

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in diagnosis and prognosis, and personalized treatment for renal cell carcinoma (RCC) session and a presentation ...
UroToday

EAU 2026: ARTO Trial: Long-Term Overall Survival Analysis from a Randomized Phase II Trial Testing the Benefit of SBRT Addition to Abiraterone in Oligometastatic CRPC Patients

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...
UroToday

EAU 2026: Debate: Optimal Management of De-Novo Oligometastatic Disease: Can't Say We Always Need PSMA PET/CT Imaging in This Setting!

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Renu Eapen discussing the optimal management of de-novo ...
UroToday

EAU 2026: Debate: Optimal Management of De-Novo Oligometastatic Disease: Intensified Systemic Therapy Is Still Mandatory

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Jozefina Casuscelli discussing the optimal management of de-novo ...
UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Umang Swami presented ...
UroToday

ASCO GU 2026: Discussant: The Era of ADCs for Urothelial Carcinoma Continues

The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
UroToday

ASCO GU 2026: Discussant: Prevention to Progression – Targeting Foundational Biology in RCC

The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...